Harnessing targeted IL-2 to reduce immunopathology and enhance immunity against respiratory virus infection

利用靶向 IL-2 来减少免疫病理并增强对呼吸道病毒感染的免疫力

• 批准号: 10680533
• 负责人: Tara Marlene Strutt
• 金额: $ 38万
• 依托单位: UNIVERSITY OF CENTRAL FLORIDA
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-22 至 2026-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10680533
• 关键词: Acute Respiratory Distress Syndrome; Adjuvant; Advanced Development; Affinity; Animals; Antibody Formation; Antiviral Agents; B-Lymphocytes; CD8-Positive T-Lymphocytes; Cells; Clinical; Combined Modality Therapy; Development; Disease; Dose; FOXP3 gene; Generations; Goals; Hospitalization; IL2RA gene; Immune; Immunity; Immunoglobulin Class Switching; Immunologic Memory; Individual; Infection; Inflammation; Inflammatory; Inflammatory Response; Influenza; Influenza A virus; Interleukin 2 Receptor; Interleukin-2; Intervention; Knowledge; Lung; Lymphocyte; Lymphoid Cell; Memory; Modeling; Mus; Names; Natural Killer Cells; Oseltamivir; Outcome; Pathway interactions; Plasma Cells; Population; Predisposition; Public Health; Regulation; Regulatory T-Lymphocyte; Reporting; Role; Shapes; Signal Transduction; Structure of germinal center of lymph node; T-Lymphocyte; Therapeutic; Therapeutic Intervention; Tissues; Treatment outcome; Vaccination; Viral; Viral Respiratory Tract Infection; Virus; Virus Diseases; antiviral immunity; cytokine release syndrome; effector T cell; global health; immunopathology; improved; improved outcome; influenza infection; innovation; inorganic phosphate; insight; memory CD4 T lymphocyte; mortality risk; novel; pre-clinical; prevent; pulmonary function; respiratory infection virus; response; tissue repair; ventilation

Influenza A virus (IAV) remains a global health concern despite annual vaccination efforts. Clinical interventions able to prevent the immunopathology and `cytokine storm' associated with severe IAV infection are urgently needed, especially approaches that can be initiated at later stages of infection. The knowledge gained from the proposed studies will facilitate the development of a novel application of an IL-2-based therapeutic approach to treat severe respiratory viral infection, as well as advance its potential use as an adjuvant to boost universal, IAV-specific immunity following vaccination.

尽管每年都进行疫苗接种工作，甲型流感病毒 (IAV) 仍然是全球健康问题。临床干预 迫切需要能够预防与严重 IAV 感染相关的免疫病理学和“细胞因子风暴” 需要，特别是可以在感染后期启动的方法。从中获得的知识 拟议的研究将促进基于 IL-2 的治疗方法的新应用的开发 治疗严重呼吸道病毒感染，并推进其作为佐剂的潜在用途，以促进普遍、 接种疫苗后产生 IAV 特异性免疫力。